Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6226 to 6240 of 7691 results

  1. Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)

    April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.

  2. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

  3. Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

    This evidence summary has been withdrawn because the product has been discontinued in the UK.

  4. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

  5. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

  6. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

  7. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

  8. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

  9. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

  10. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

    This guideline has been updated and replaced by NICE guideline NG131.

  11. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

    Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

  12. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

    This guidance has been updated and replaced by NICE interventional procedures guidance 752.

  13. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585)

    This guidance has been updated and replaced by NICE interventional procedures guidance 749.